Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study
in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also
participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized
to 1 of 3 treatment regimens for 3 months.